Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2019

View Archived Issues

Anti-RSV agent ziresovir demonstrates promising preclinical profile

PDX model allows study of hepatitis B virus in hepatocellular carcinoma

Targeting NuRD for derepression of fetal hemoglobin in hemoglobinopathies

MSH3 linked to somatic expansion and disease phenotype in Huntington's disease and DM1

First patient enrolled in phase II study of AR-201 for egg allergy

MyoKardia initiates dosing in phase I study of MYK-224 for hypertrophic cardiomyopathy

Glenmark receives approval for combination of remogliflozin and metformin in India

Phase I data presented for CM-101 subcutaneous formulation

Shinkei Therapeutics files IND application with the FDA for MR-201

Discovery of novel antisense oligonucleotides for the treatment of prion disease

Discovery and preclinical evaluation of SH-379 as a novel anti-LOH agent

Results presented from phase III HOPE study of voxelotor in sickle cell disease

Eisai describes new aldehyde dehydrogenase-2 activators

Bruton tyrosine kinase inhibitors discovered at Merck & Co.

Pfizer identifies Gly12Cys mutant GTPase KRas inhibitors

Placental growth factor may be autoimmune disease target

Sichuan Kelun-Biotech Biopharmaceutical patents C-C chemokine receptor type 2/5 antagonists

Shenzhen Bo Li Jian Medicine discloses new mutant EGFR inhibitors

Japanese approval for Darzalex in newly diagnosed multiple myeloma

China's NMPA approves roxadustat for anemia in patients with CKD not receiving dialysis

Lonsurf approved in Japan for advanced gastric cancer

Could orphan opioid receptor prevent opioid orphans?

Identifying the cause of lupus cognitive dysfunction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...